GLP-1s and Pancreatitis: What the Label Says, What the Research Shows and the Warning Signs to Know

Pancreatitis is one of the side effects that makes people pause before starting a GLP-1 medication such as semaglutide (Wegovy, Ozempic) or tirzepatide (Zepbound, Mounjaro). It is printed in the warnings section of every one of these labels, it shows up regularly in news stories and social media posts, and the word itself sounds alarming.

This guide explains what the warning actually says, how often pancreatitis happened in the clinical trials, what the larger body of research and drug-safety regulators have found, who may be at higher risk, and the symptoms that mean you should stop your dose and get care right away.

Educational only. This is not medical advice. If you take a GLP-1 medication and develop severe stomach pain that does not go away, with or without vomiting, stop your dose and contact your prescriber right away, or seek urgent care. Do not stop or change your medicine for other reasons without talking to your prescriber.

The short answer

Acute pancreatitis is a real but uncommon risk with GLP-1 medicines. In the Wegovy weight-loss trials, acute pancreatitis was confirmed in 4 people taking Wegovy (0.2 cases per 100 patient-years) versus 1 on placebo (less than 0.1). In two main Zepbound weight-loss trials, it was confirmed in 0.2% of people on the drug and 0.2% on placebo.

Large meta-analyses of randomized trials, which pool tens of thousands of participants, have mostly found little or no clear increase in pancreatitis risk. Still, some observational studies have found a higher rate, and drug-safety systems have collected rare reports of severe and even fatal cases. That is why the labels tell clinicians to stop the medicine if pancreatitis is suspected, and why every person on a GLP-1 should know the one symptom that matters most: severe stomach pain that will not go away, often spreading to the back.

What pancreatitis is

The pancreas is a gland that sits behind the stomach in the upper belly. It makes digestive enzymes that help break down food, and hormones such as insulin that help control blood sugar.

Pancreatitis means the pancreas is inflamed. According to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of the National Institutes of Health, it happens when digestive enzymes become active while still inside the pancreas and start to irritate and damage it. There are two main forms:

• Acute pancreatitis comes on suddenly. NIDDK says it leads to about 275,000 hospital stays in the United States each year, and that most people get better within several days with treatment. Some cases are severe and can cause serious complications.
• Chronic pancreatitis is long-lasting inflammation that does not heal and can get worse over time.

The warning on GLP-1 labels is about acute pancreatitis. Severe forms include “hemorrhagic” pancreatitis (with bleeding) and “necrotizing” pancreatitis (where part of the pancreas tissue dies).

What usually causes it

NIDDK lists gallstones as the most common cause of acute pancreatitis. A stone can travel out of the gallbladder and block the duct the pancreas drains through. Heavy alcohol use is another common cause, along with very high triglycerides (a type of blood fat), certain genetic conditions and some medicines.

NIDDK also lists factors that make pancreatitis more likely, including obesity, diabetes, high triglycerides, smoking, gallstones, heavy drinking and a family history of pancreatitis. Many of these are common in the people who are prescribed GLP-1 medicines, which is one reason the link has been so hard to untangle.

What the GLP-1 labels say

The US prescribing information for Wegovy and Zepbound uses almost the same wording. Acute pancreatitis, “including fatal and non-fatal hemorrhagic or necrotizing pancreatitis,” has been observed in patients treated with GLP-1 receptor agonists and with the drug itself. Clinicians are told to watch for signs and symptoms, including persistent severe abdominal pain that sometimes radiates to the back, with or without vomiting. If pancreatitis is suspected, the drug should be discontinued and appropriate management started.

The Wegovy Medication Guide puts it in patient language: “Stop using WEGOVY and call your healthcare provider right away if you have severe pain in your stomach area (abdomen) that will not go away, with or without nausea or vomiting. Sometimes you may feel the pain from your abdomen to your back.” The Zepbound Medication Guide gives the same instruction.

Two things are not in the label. Pancreatitis is not a contraindication, meaning a firm “do not take,” and the labels do not call for routine blood tests of pancreatic enzymes. The only listed contraindications are a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, and a prior serious allergic reaction to the drug. We explain the difference between warnings and contraindications in Who Should Not Take a GLP-1 Medication?.

How often it happened in trials

The labels summarize the cases confirmed by an independent committee (a process called adjudication) in the clinical trials:

Medicine and trials	Drug group	Comparison group
Wegovy (semaglutide), adult weight-loss trials	4 people, 0.2 cases per 100 patient-years	1 person, less than 0.1 per 100 patient-years
Zepbound (tirzepatide), two weight-loss trials	0.2% (0.14 per 100 years of exposure)	0.2% on placebo (0.15 per 100 years)
Zepbound, two sleep apnea trials	0.84 per 100 years	0 on placebo
Tirzepatide, trials for another indication (type 2 diabetes)	13 people, 0.23 per 100 years	3 people, 0.11 per 100 years
Saxenda (liraglutide), weight-loss trials	9 of 3,291 people (0.3%)	2 of 1,843 on placebo (0.1%)

The Wegovy label notes one additional confirmed case in another trial. The Saxenda label describes two more cases in people who had already stopped the drug early (74 and 124 days after the last dose) and two in people off treatment, one within two weeks of stopping and one 106 days after.

A rate of 0.2 cases per 100 patient-years means roughly two cases for every 1,000 people treated for a year. The numbers are small, and the confidence around them is wide, because so few events happened in total.

After approval: rare severe cases

Both the Wegovy and Zepbound labels list acute pancreatitis, including necrotizing and hemorrhagic forms, among the reactions reported after approval, sometimes resulting in death. These post-marketing reports are voluntary and come from an unknown number of users, so they cannot tell us how often something happens or prove that the drug caused it. They do show that severe cases, while rare, are possible.

The lipase and amylase question

Lipase and amylase are pancreatic enzymes that doctors measure in the blood when they suspect pancreatitis. GLP-1 medicines raise them a little on average, even in people who feel completely well:

• Wegovy: in the weight-loss trials, mean lipase rose 39% and amylase 15% to 16% from baseline. These changes were not seen in the placebo group. In a trial in adults with MASH (a type of fatty liver disease), lipase above three times the upper limit of normal occurred in 4.7% of people on Wegovy (35 of 750) versus 1.3% on placebo (5 of 374).
• Zepbound: in the two main weight-loss trials, mean lipase rose 28% to 35% and pancreatic amylase 20% to 25%, compared with 5.8% and 2.1% on placebo.

Both labels state that the clinical significance of these enzyme rises is unknown in the absence of other signs and symptoms of pancreatitis. In practice, that means a mildly raised lipase on a routine blood test is not the same thing as pancreatitis. It is one reason symptoms, not a single lab value, are what doctors focus on.

What the larger research shows

Individual trials are too small to settle the question, so researchers pool them. Here is what several meta-analyses of randomized trials found:

• Monami and colleagues, 2017 (Diabetes, Obesity and Metabolism): across 113 trials of GLP-1 medicines in type 2 diabetes, there was no significant increase in pancreatitis (odds ratio 0.93) or pancreatic cancer. Gallstones, by contrast, were significantly more common.
• Zeng and colleagues, 2023 (Frontiers in Endocrinology): across 9 tirzepatide trials with 9,871 participants, the pancreatitis risk ratio was 1.46, but the confidence interval (0.59 to 3.61) was wide and the result was not statistically significant.
• Masson and colleagues, 2024 (Endocrinología, Diabetes y Nutrición): across 21 semaglutide trials with 34,721 patients, there was no increased risk of acute pancreatitis (odds ratio 0.7, confidence interval 0.5 to 1.2) with oral, low-dose or high-dose semaglutide.
• Chiang and colleagues, 2025 (Gastroenterology): across 55 trials with 106,395 participants, GLP-1 medicines increased gallstones and reflux, but probably had little or no effect on other digestive and biliary events, pancreatitis included.
• Wen and colleagues, 2025 (Endocrinology, Diabetes & Metabolism): across 62 trials with 66,232 patients, the overall risk ratio for pancreatitis was 1.44 (1.09 to 1.89). However, the difference was not significant when trials were grouped by background medication, and the authors judged the real difference to be likely minimal, partly because many trials recorded zero cases.

Observational studies of real-world prescriptions sometimes point the other way. A 2023 research letter in JAMA by Sodhi and colleagues used insurance claims from people with obesity but no diabetes. Pancreatitis occurred at 4.6 cases per 1,000 person-years on semaglutide and 7.9 on liraglutide, versus 1.0 on bupropion-naltrexone, a non-GLP-1 weight-loss pill. The adjusted hazard ratio was 9.09, but the 95% confidence interval stretched from 1.25 to 66.00, which tells you how few events there were. Studies like this can show an association, but they cannot fully account for differences between people who get one drug versus another.

Putting it together: the best randomized evidence does not show a large or clear increase in pancreatitis, but small increases cannot be ruled out, and severe individual cases do happen. That is a fair summary of why the warning stays on the label.

What regulators are saying in 2026

In January 2026, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) strengthened its warnings for the whole class, including liraglutide, semaglutide and tirzepatide, to highlight rare reports of necrotizing and fatal pancreatitis. Between 2007 and October 2025, the MHRA received 1,296 reports of pancreatitis linked to these medicines through its Yellow Card reporting scheme, 19 of them fatal and 24 described as necrotizing. For context, it estimated that roughly 25.4 million packs were dispensed in the UK over the past five years.

The MHRA’s advice to clinicians includes:

• Stop the GLP-1 immediately if pancreatitis is suspected.
• Do not restart it if pancreatitis is confirmed.
• Use these medicines with caution in people with a history of pancreatitis.
• Ask patients with these symptoms whether they take a GLP-1, because privately prescribed medicines may not appear in their medical record.

The agency called the risk “very small” and described GLP-1s as safe and effective for most patients. It is also running a genetic study, the Yellow Card Biobank with Genomics England, to explore whether a person’s genes influence their pancreatitis risk on these medicines.

Why the link is hard to pin down

Several things make GLP-1s and pancreatitis tricky to study:

1. Pancreatitis is rare in trials. With only a handful of cases per thousand people, small differences between groups can appear or disappear by chance.
2. The people treated already have higher baseline risk. Obesity, type 2 diabetes and high triglycerides are all NIDDK-listed risk factors for pancreatitis.
3. Gallstones may be part of the story. GLP-1 medicines are linked to more gallstones, and gallstones are the most common cause of acute pancreatitis. Some cases blamed on the drug may begin in the gallbladder. Our guide to GLP-1s and gallbladder problems explains that link in detail.
4. Enzyme rises cloud the picture. Because lipase and amylase go up a little on treatment, a blood test alone can be misleading.

In a teaching video for clinicians on YouTube, Dr. Lee-Shing Chang, an endocrinologist at Brigham and Women’s Hospital, sums up the position many prescribers take: GLP-1s should be used with caution in people with a history of pancreatitis because some studies showed a possible signal, “although this has not been definitively proven.”

Who may be at higher risk

No test can predict who will get pancreatitis on a GLP-1, but your risk is likely higher if you have:

• a past episode of pancreatitis, especially if the cause is unknown or still present;
• gallstones or a history of gallbladder attacks;
• heavy alcohol use;
• very high triglycerides;
• a family history of pancreatitis or a known genetic condition affecting the pancreas;
• smoking.

Tell your prescriber about any of these before you start, and if anything changes during treatment. If alcohol is part of your life, our guide to alcohol and GLP-1s covers how drinking interacts with these medicines.

The warning signs, and what to do

The symptom every person on a GLP-1 should know is severe pain in the upper stomach area that does not go away. It often spreads to the back, and it may or may not come with nausea or vomiting. NIDDK adds that acute pancreatitis can cause:

• fever;
• a fast heartbeat;
• a swollen or tender belly;
• nausea and vomiting.

People with acute pancreatitis usually look and feel seriously ill. If you have these symptoms, stop your next dose and contact your prescriber right away. Seek urgent or emergency care for pain that is severe or getting worse, vomiting you cannot stop, fever or chills, a racing heartbeat, shortness of breath, or yellowing of your skin or eyes. Tell the care team you take a GLP-1 medicine and which one, especially if it was prescribed online or through a private clinic.

Pancreatitis pain vs everyday GLP-1 stomach symptoms

Stomach upset is the most common side effect of GLP-1 medicines, so it helps to know how pancreatitis usually feels different:

	Common GLP-1 stomach side effects	Possible pancreatitis
Severity	Usually mild to moderate	Often severe
Pattern	Comes and goes; often worst after a dose increase and eases over days to weeks	Constant and does not go away
Location	Vague, all over the belly, or bloating	Upper belly, often spreading to the back
How you feel overall	Uncomfortable but able to function	Usually seriously ill; may have fever or fast heartbeat
What to do	Self-care steps; tell your prescriber if it persists	Stop your dose and get care right away

These are general patterns, not rules. If you are unsure, get checked. For the everyday side effects, see our guides to GLP-1 nausea and constipation and diarrhea on GLP-1s.

How doctors diagnose and treat it

According to NIDDK, doctors diagnose acute pancreatitis from your symptoms, a physical exam and blood tests that include lipase and amylase. They may also order imaging such as an abdominal ultrasound (which can show gallstones), a CT scan or a special MRI of the bile and pancreatic ducts.

Treatment usually happens in the hospital and focuses on supportive care: fluids through a vein, pain relief and, once you can eat, a low-fat diet. Antibiotics are used if there is infection. If gallstones caused the attack, doctors may recommend removing the gallbladder or a procedure to clear a blocked duct. NIDDK also advises stopping alcohol and smoking.

Your care team will stop the GLP-1. Whether you can ever take one again is a decision for your clinicians. The MHRA’s position is that the medicine should not be restarted if pancreatitis is confirmed. Earlier versions of the US Wegovy label said the same, and the current US labels say to discontinue if pancreatitis is suspected.

If you have had pancreatitis before

A past episode does not automatically rule out a GLP-1 on the US labels, but it calls for a careful conversation. Questions your clinician will likely weigh include:

• What caused it? An episode caused by gallstones that were then dealt with, for example by removing the gallbladder, is a different situation from one with no clear cause or an ongoing cause.
• Did it happen on a GLP-1 or a similar medicine? If so, regulators such as the MHRA advise against restarting.
• Are risk factors still present? Heavy drinking, very high triglycerides and gallstones all matter.
• Are there other options? Some people may be better served by a different approach to weight management.

Our guide to who should not take a GLP-1 covers this and other cautions side by side.

Ways to lower the risks you can control

There is no proven way to prevent GLP-1-related pancreatitis, but you can reduce some of the known risk factors:

• Be honest about alcohol. Heavy drinking is one of the most common causes of pancreatitis.
• Protect your gallbladder. Avoid very long fasts and extreme calorie cuts, eat regular meals, include fiber and some healthy fats, and aim for a steady pace of weight loss. See what to eat on GLP-1s for practical meal ideas.
• Know your triglycerides. If you have had very high levels, ask your clinician how they are being managed.
• Stop smoking if you smoke; it is a listed risk factor.
• Use a legitimate prescriber and pharmacy. Proper medical oversight means someone reviews your history before you start and is reachable if symptoms appear. Our guide to spotting unsafe online GLP-1 sellers explains what to look for.
• Keep your prescriber informed. Report new or unusual stomach pain early rather than waiting it out.

What people are asking online

On X, the pancreatitis question comes up constantly, and the tone ranges from calm to alarmed. Some posts list pancreatitis alongside other side effects as if it were common; others point out, correctly, that a history of pancreatitis is a warning on the labels rather than a formal contraindication. A recurring and sensible point in these threads is that fast weight loss raises gallstone risk on its own, which makes it hard to separate the drug’s effect from the effect of losing weight.

The honest picture sits between the extremes: pancreatitis is uncommon, the best trial data do not show a large increase, and serious cases are rare but real. Knowing the symptoms is more useful than either worrying or dismissing the risk.

Questions to ask your prescriber

1. Does anything in my history, such as gallstones, past pancreatitis, alcohol use or high triglycerides, raise my risk?
2. Do you want any blood tests before I start, and how should I interpret enzyme results if they are checked later?
3. What exactly should I do, and who should I call, if I get severe stomach pain, including at night or on weekends?
4. How will we adjust my plan if I have stomach side effects during dose increases?
5. If I had pancreatitis on this medicine, what would my options be afterward?

The bottom line

Pancreatitis is a labeled warning for every GLP-1 weight-loss medicine, but it is uncommon. In the main Wegovy and Zepbound weight-loss trials, cases were rare and close to placebo rates, and large meta-analyses of randomized trials have mostly found little or no clear increase in risk. Rare severe and fatal cases have been reported, and regulators strengthened their warnings in 2026 for that reason.

For most people, the practical takeaway is simple: tell your prescriber about your history before you start, and if you ever develop severe stomach pain that does not go away, often spreading to your back, stop your dose and get medical care right away. For more on side effects and serious risks, visit our Side Effects hub, or start with the basics in our GLP-1 Guide.